BridgeBio Pharma, Inc.: UBS raises target price to $92 from $82
BBIO•UBS raised its target price for BridgeBio Pharma to $92 from $82.
Related News
Alnylam Pharmaceuticals: UBS cuts target price to $354 from $550
ALNY•
US yields fall as investors look for safety and bet on pause in rate hikes
TLT•
US holiday sales growth to speed up as shoppers stay resilient, NRF forecasts
XLY•
EQT Corporation: UBS cuts target price to $76 from $77
EQT•
Block, Inc.: UBS cuts target price to $96 from $98
XYZ•